Welcome to our dedicated page for BIONTECH news (Ticker: BNTX), a resource for investors and traders seeking the latest updates and insights on BIONTECH stock.
BioNTech SE reports recurring developments as a Germany-based biotechnology company whose ADSs trade on Nasdaq. Company news centers on oncology pipeline progress across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies, including lung cancer programs such as pumitamig and gotistobart, as well as COVID-19 vaccine activity tied to its commercial vaccine franchise.
Updates also cover quarterly and annual financial results, research and development spending, corporate presentations, capital allocation actions such as ADS repurchase authorizations, and shareholder meeting or governance matters. BioNTech news frequently links clinical data, partnership activity and operating priorities to its broader objective of building a multi-product biotechnology business.
Summary not available.
Pfizer and BioNTech announced the U.S. government's order of an additional 100 million doses of the COVID-19 vaccine, raising the total to 200 million doses. All doses will be manufactured in the U.S. and expected for delivery by July 31, 2021. The U.S. government will invest $1.95 billion for these doses. The companies aim to provide free vaccine access to eligible U.S. residents. The vaccine is authorized under an Emergency Use Authorization, with delivery timelines set to ensure widespread vaccination availability.
Pfizer and BioNTech announced a new agreement with the U.S. government to supply an additional 100 million doses of their COVID-19 vaccine, bringing the total to 200 million doses. The U.S. will pay $1.95 billion for this order, with delivery expected by July 31, 2021. At least 70 million doses are to be delivered by June 30, 2021. The vaccine, authorized for emergency use, is provided free to eligible U.S. residents. The companies aim to ensure widespread vaccine access to combat the pandemic.
BioNTech will host a press conference on December 22, 2020, to update on the COVID-19 vaccine candidate BNT162b2. The virtual event starts at 09:00 CET / 03:00 ET, and journalists can submit questions online. Access to the event is available via BioNTech's website, with a recording provided post-conference. BioNTech is focused on pioneering therapies for cancer and infectious diseases, leveraging advanced mRNA technology and collaborations with major pharmaceutical partners.
The European Commission has granted conditional marketing authorization (CMA) for Pfizer and BioNTech's COVID-19 vaccine, COMIRNATY, for individuals aged 16 and older. This follows a positive opinion from the EMA's Committee for Medicinal Products. The CMA is valid across all 27 EU member states, aiming to combat the COVID-19 pandemic. Notably, the vaccine demonstrated a 95% efficacy rate in a pivotal Phase 3 trial involving over 44,000 participants. The rollout of 200 million doses is set to begin immediately, with production at sites in Germany and Belgium.
BioNTech and Pfizer have received conditional marketing authorization from the European Commission for their mRNA vaccine, COMIRNATY (BNT162b2), to prevent COVID-19 in individuals aged 16 and older. This historic achievement is based on data from a large-scale trial involving over 44,000 participants and demonstrates a vaccine efficacy rate of 95%. The EU has ordered 200 million doses, with an option for 100 million more. Immediate distribution will commence across all 27 EU member states, with ongoing monitoring of efficacy and safety for two additional years.
Pfizer and BioNTech announced a positive opinion from the EMA's CHMP recommending conditional marketing authorization for their COVID-19 vaccine (BNT162b2) for individuals 16 and older. This CMA allows for expedited approval in response to serious public health threats. The positive recommendation is based on Phase 3 clinical study data, which supports the vaccine's efficacy against COVID-19. If authorized by the European Commission, the vaccine will be available across all EU member states. The vaccine is already authorized for emergency use in over 15 countries.
The European Medicines Agency (EMA) has provided a positive opinion recommending conditional marketing authorization for the Pfizer-BioNTech COVID-19 vaccine (BNT162b2). If authorized by the European Commission, it will be the first COVID-19 vaccine available in the EU. Based on extensive Phase 3 data, the vaccine aims to combat COVID-19 for individuals aged 16 and older. This positive opinion follows numerous emergency use authorizations globally, and the vaccine has already been approved in over 15 countries.
BioNTech (BNTX) and Fosun Pharma announced a supply agreement for 100 million doses of the BNT162 mRNA COVID-19 vaccine in China, pending regulatory approval. The initial supply will come from BioNTech's facilities in Germany. This collaboration aims to enhance vaccine accessibility and affordability in China. A Phase 2 clinical trial for BNT162b2 is ongoing in Jiangsu Province, involving 960 participants to assess safety and immunogenicity. Both companies express gratitude towards the Chinese authorities for their support in combating COVID-19.
BioNTech (Nasdaq: BNTX) and Pfizer announced significant findings from their Phase 1/2 trial of the COVID-19 vaccine BNT162b2. The study involving 37 participants showed a robust immune response, including broad SARS-CoV-2-specific neutralizing antibodies, CD4+ T cell responses, and strong CD8+ T cell activation. Notably, all participants produced neutralizing antibodies, and the vaccine effectively targeted multiple spike protein regions. These results affirm a strong safety profile and sustained immune response, indicating potential for broad protection against diverse virus variants.